Arcus Biosciences Inc logo

RCUS - Arcus Biosciences Inc News Story

$34.55 -1.7  -4.7%

Last Trade - 03/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.84bn
Enterprise Value £1.32bn
Revenue £55.6m
Position in Universe 1972nd / 6642

BRIEF-Arcus Biosciences Presents Promising Initial Data From Phase 1 Portion Of Arc-8 Study For Ab680 In Metastatic Pancreatic Cancer

Fri 15th January, 2021 1:05pm
Jan 15 (Reuters) - Arcus Biosciences Inc  RCUS.N :
    * ARCUS BIOSCIENCES PRESENTS PROMISING INITIAL DATA FROM
PHASE 1
PORTION OF ARC-8 STUDY FOR AB680 IN METASTATIC PANCREATIC CANCER
    * ARCUS BIOSCIENCES INC - INITIATED PHASE 1B EXPANSION
PORTION OF
STUDY
    * ARCUS BIOSCIENCES - 41% ORR OBSERVED TO-DATE ACROSS FIRST
FOUR
COHORTS IN PHASE 1 DOSE-ESCALATION PORTION OF ARC-8

Source text for Eikon:  ID:nBw35Gk7za 
Further company coverage:  RCUS.N 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.